Live Breaking News & Updates on Takeda Vpriv

China National Healthcare Security Administration NHSA published 2022 National Reimbursement Drug List 2022 NRDL, implementing comparable level of pricing discounts to those seen in 2021. Out of 147 drugs negotiated, 121 were successfully added to 2022 NRDL, including 91 exclusive. ....

Novartis Kesimpta , Abbvie Venclexta , Brii Bioscience Amubarvimab , Takeda Vpriv , Takeda Alunbrigtm , Roche Sylvant , Junsi Biosciences , Takeda Takhzyro , Novartis Zolgensma , Henlius Serplulimab , Takeda Alglucosidase , Roche Risdiplam , Cstone Pharmaceuticals , National Health Commission , China National Healthcare Security Administration , National Reimbursement Drug List , National Medical Products Administration , National Healthcare Security Administration , Insurance Resource Spending At National Level , National Medical Insurance , Reimbursement Drug List , Effective Date , Consistent Price Cut , Medical Insurance Resource Spending , Genuine Biotech , Although Simnotrelvir ,